Formulary guidance and transparency from P&T to point of care

Trends That Matter for CMS Proposed Guidelines

Posted by Matt Breese on Aug 10, 2017

Find me on:


In our weekly Trends that Matter series, we provide engaging infographics, articles and recent news from healthcare influencers to highlight general trends affecting the pharmaceutical industry. This week's featured topic is the CMS' new proposed guidelines for drug discounts.

The Centers for Medicare & Medicaid Services (CMS) recently released a proposal to reduce certain drug reimbursements for the 340B Program.  

What exactly does this plan entail? According to Richard P. Church, Partner at K & L Gates:

"The Centers for Medicare and Medicaid Services (CMS) recently proposed as part of its Calendar Year 2018 update to the Outpatient Prospective Payment System (OPPS) to reduce Medicare Part B drug reimbursement for 340B Program covered entities to the drug’s average sales price (ASP) minus 22.5%."
Furthermore, some industry players are questioning the lawfulness of this proposal. According to Morgan Lewis at JD Supra:
"The agency’s recent proposal to reduce certain drug reimbursement is unprecedented and not based on a reasonable interpretation of its statutory authority."

Subscribe to the MMIT blog for more insights on trends affecting pharmaceutical manufacturers, providers and payers.

Subscribe for Weekly Trends that Matter

Topics: Industry Trends